“At Biotage the focus is on
developing technology to speed up and simplify experimental procedures
while simultaneously driving down operating costs. Whether the customer
is a Pharma development group, a CRO focused on cost and productivity or
an Academic researcher focused on unique sequences, the Syro Wave™
fits.”
Biotage (STO:BIOTA), a leading supplier of tools and technology for
medicinal and analytical chemistry, today announced the eagerly awaited
global launch of the Syro Wave™; their new microwave and parallel
peptide synthesizer. The Syro Wave™ is a result of the joint development
project announced last year between Biotage and MultiSynTech. It
combines the proven performance of the established MultiSynTech robotic
synthesizer with Biotage microwave technology.
The Syro Wave™ peptide synthesis system is the only system on the market
that offers both microwave and parallel peptide synthesis capabilities.
To date peptide synthesis labs have been required to invest in both
standalone parallel systems for productivity and cost efficiency, and
standalone microwave systems for difficult or longer peptides. This
results in increased demand on bench space, duplication of computer
control systems, and multiple operating software platforms for chemists
to learn and maintain. Biotage has addressed these shortcomings with the
Syro Wave™, containing both parallel and microwave technologies on the
same platform.
The new Biotage Syro Wave™ increases productivity, yield and purity
while cutting costs and saving time. “At Biotage the focus is on
developing technology to speed up and simplify experimental procedures
while simultaneously driving down operating costs. Whether the customer
is a Pharma development group, a CRO focused on cost and productivity or
an Academic researcher focused on unique sequences, the Syro Wave™
fits.” noted Scott Carr, Vice President Commercial Operations, Biotage.